- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
GSK Announces US Vaccine R&D Center
GlaxoSmithKline announces global vaccines research and design facility to be based in Rockville, MD, USA.
GlaxoSmithKline (GSK) announced on April 2, 2015 that it would expand its global vaccines production capabilities with a new facility in Rockville, MD, USA. This will be the third GSK global vaccines R&D center, in addition to the company’s existing facilities in Rixensart, Belgium and Siena, Italy (a site acquired from Novartis in March 2015).
According to a press release, GSK’s other US facilities conducting vaccine R&D, including the Philadelphia, PA and Cambridge, MA sites, will be consolidated to the Rockville location. The announcement of the new location follows the March 2015 close of the three-part transaction between Novartis and GSK. In April 2014, Novartis and GSK announced that they would trade assets, resulting in the Novartis acquisition of GSK’s oncology business, and GSK’s acquisition of Novartis’ vaccine business.
“Following the acquisition of Novartis’s global vaccines business and in recognition of the vaccines knowledge and expertise in the United States, we are pleased to expand our US presence with the creation of a world-class vaccines R&D center. This will drive innovation, and enhance our capabilities for new vaccine discoveries that protect the US and public health around the world,” said Luc Debruyne, president of GSK Vaccines, in a press release.
Source: GSK
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Novel GLP-1 Receptor Agonist Demonstrates Promising Results Treating Patients with Obesity
January 21st 2025Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a half-life of up to 60 hours, and superior pharmacokinetic properties compared to other oral GLP-1 receptor agonists.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Artificial Intelligence Makes Possible a Multiomic Approach in Oncology Drug Discovery
January 7th 2025While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates more quickly and efficiently with applications in target discovery, structure prediction, and drug optimization.
